Euroopa Liit - eesti - EMA (European Medicines Agency)

incyte biosciences distribution b.v. - ruxolitinib phosphate - vitiligo - muud dermatoloogilised preparaadid - opzelura is indicated for the treatment of non-segmental vitiligo with facial involvement in adults and adolescents from 12 years of age.

Euroopa Liit - eesti - EMA (European Medicines Agency)

novartis europharm limited - ruxolitiniib (fosfaadina) - myeloproliferative disorders; polycythemia vera; graft vs host disease - antineoplastilised ained - myelofibrosis (mf)jakavi is indicated for the treatment of disease related splenomegaly or symptoms in adult patients with primary myelofibrosis (also known as chronic idiopathic myelofibrosis), post polycythaemia vera myelofibrosis or post essential thrombocythaemia myelofibrosis. polycythaemia vera (pv)jakavi on näidustatud ravi täiskasvanud patsientidel, kellel polycythaemia vera, kes on resistentsed või sallimatu hydroxyurea. graft versus host disease (gvhd)jakavi is indicated for the treatment of patients aged 12 years and older with acute graft versus host disease or chronic graft versus host disease who have inadequate response to corticosteroids or other systemic therapies (see section 5.

Euroopa Liit - eesti - EMA (European Medicines Agency)

bristol myers squibb pharma eeig - fedratinib dihydrochloride monohydrate - myeloproliferative disorders; primary myelofibrosis - antineoplastilised ained - inrebic is indicated for the treatment of disease-related splenomegaly or symptoms in adult patients with primary myelofibrosis, post polycythaemia vera myelofibrosis or post essential thrombocythaemia myelofibrosis who are janus associated kinase (jak) inhibitor naïve or have been treated with ruxolitinib.

Euroopa Liit - eesti - EMA (European Medicines Agency)

accord healthcare s.l.u. - sunitiniib - gastrointestinal stromal tumors; carcinoma, renal cell; neuroendocrine tumors - antineoplastilised ained - gastrointestinal stromal tumour (gist)sunitinib accord is indicated for the treatment of unresectable and/or metastatic malignant gastrointestinal stromal tumour (gist) in adults after failure of imatinib treatment due to resistance or intolerance. metastatic renal cell carcinoma (mrcc)sunitinib accord is indicated for the treatment of advanced/metastatic renal cell carcinoma (mrcc) in adults. pancreatic neuroendocrine tumours (pnet)sunitinib accord is indicated for the treatment of unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumours (pnet) with disease progression in adults.

Eesti - eesti - Ravimiamet

sandoz pharmaceuticals d.d. - sunitiniib - kõvakapsel - 25mg 110tk; 25mg 28tk; 25mg 56tk; 25mg 30tk; 25mg 100tk; 25mg 90tk; 25mg 70tk; 25mg 98tk; 25mg 84tk

Eesti - eesti - Ravimiamet

sandoz pharmaceuticals d.d. - sunitiniib - kõvakapsel - 50mg 30tk

Eesti - eesti - Ravimiamet

sandoz pharmaceuticals d.d. - sunitiniib - kõvakapsel - 12,5mg 30tk

Eesti - eesti - Ravimiamet

sandoz pharmaceuticals d.d. - sunitiniib - kõvakapsel - 37,5mg 84tk; 37,5mg 30tk; 37,5mg 56tk; 37,5mg 28tk

Eesti - eesti - Ravimiamet

teva b.v. - sunitiniib - kõvakapsel - 50mg 28tk; 50mg 30tk

Eesti - eesti - Ravimiamet

teva b.v. - sunitiniib - kõvakapsel - 12,5mg 30tk